China Biologic Products, Inc. (NASDAQ:CBPO) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Monday.

According to Zacks, “China Biologic Products, Inc., through its indirect majority-owned subsidiary, is principally engaged in the research, development, production, manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. Its subsidiary, Shandong Taibang Biological Products Co. Ltd., operates from its manufacturing facility located in Taian City, Shandong Province. The Company’s principal products include its approved human albumin and immunoglobulin products. These human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases. “

Several other research firms also recently issued reports on CBPO. BidaskClub downgraded shares of China Biologic Products from a “hold” rating to a “sell” rating in a report on Sunday, July 16th. Goldman Sachs Group, Inc. (The) initiated coverage on shares of China Biologic Products in a report on Tuesday, May 30th. They set a “neutral” rating on the stock. Finally, Jefferies Group LLC restated a “buy” rating and set a $140.00 price objective on shares of China Biologic Products in a report on Monday, June 12th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $132.00.

Shares of China Biologic Products (NASDAQ:CBPO) traded down 1.30% during mid-day trading on Monday, hitting $95.78. 196,125 shares of the stock were exchanged. China Biologic Products has a 52-week low of $95.43 and a 52-week high of $137.38. The stock has a 50-day moving average price of $105.95 and a 200 day moving average price of $108.21. The firm has a market cap of $2.61 billion, a price-to-earnings ratio of 24.93 and a beta of 1.70.

China Biologic Products (NASDAQ:CBPO) last released its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $1.35 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.30 by $0.05. The business had revenue of $89.28 million during the quarter, compared to analyst estimates of $97.33 million. China Biologic Products had a net margin of 31.55% and a return on equity of 21.86%. The company’s quarterly revenue was down 2.3% on a year-over-year basis. During the same period in the prior year, the firm posted $1.26 earnings per share. On average, equities research analysts expect that China Biologic Products will post $4.95 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “China Biologic Products, Inc. (NASDAQ:CBPO) Rating Lowered to Sell at Zacks Investment Research” was originally published by Daily Political and is the property of of Daily Political. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.dailypolitical.com/2017/08/07/china-biologic-products-inc-nasdaqcbpo-rating-lowered-to-sell-at-zacks-investment-research.html.

In other news, insider Zhijing Cbpo Liu sold 7,500 shares of the company’s stock in a transaction dated Tuesday, May 9th. The shares were sold at an average price of $116.49, for a total transaction of $873,675.00. Following the transaction, the insider now owns 10,969 shares in the company, valued at $1,277,778.81. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 2.73% of the company’s stock.

Several institutional investors have recently bought and sold shares of the stock. FMR LLC increased its position in China Biologic Products by 27.5% in the first quarter. FMR LLC now owns 1,880,549 shares of the biopharmaceutical company’s stock valued at $188,300,000 after buying an additional 406,105 shares during the period. BlackRock Inc. increased its position in China Biologic Products by 694.1% in the first quarter. BlackRock Inc. now owns 1,508,096 shares of the biopharmaceutical company’s stock valued at $151,007,000 after buying an additional 1,318,183 shares during the period. FIL Ltd increased its position in China Biologic Products by 3.2% in the first quarter. FIL Ltd now owns 878,769 shares of the biopharmaceutical company’s stock valued at $87,991,000 after buying an additional 27,493 shares during the period. Hermes Investment Management Ltd. increased its position in China Biologic Products by 3.2% in the second quarter. Hermes Investment Management Ltd. now owns 651,117 shares of the biopharmaceutical company’s stock valued at $73,641,000 after buying an additional 19,893 shares during the period. Finally, Bank of New York Mellon Corp increased its position in China Biologic Products by 4.1% in the second quarter. Bank of New York Mellon Corp now owns 586,459 shares of the biopharmaceutical company’s stock valued at $66,328,000 after buying an additional 22,932 shares during the period. Hedge funds and other institutional investors own 74.09% of the company’s stock.

About China Biologic Products

China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment.

Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.